

**Amendments to the Specification:**

Please insert the Sequence Listing being filed concurrently herewith into the specification.

Please amend paragraph [0162] on page 53 as follows:

**[0162]** **Results and Discussion:** The concentration of substrate converted to product was plotted as a function of time. The initial cleavage rate ( $V_o$ ) was obtained from the slope (pM converted substrate per minute) of the best-fit line derived from  $\geq 5$  data points within the linear portion (< 10% of the total reaction) of the plot. The errors reported were based on three trials and is shown in the table below:

Sample	$V_o$ (pM/min)	P	Sequence
2302	$4.48 \pm 0.81$	-	5'-GCCCAAGCTGGCATCCGTCA (SEQ ID NO.: 1)
2302-TPT	$25.91 \pm 3.30$	0.001	5'-GCCCAAGCTGGCATCCGTC-PSO <sub>2</sub> (SEQ ID NO.: 2)

Analysis of the above table shows that the 3'-TPT species behaves better than the parent drug ( $V_o = 25.91 \pm 3.30$ ) and is approximately six times more potent (P = 0.001) than SEQ ID NO:1.

Please amend Table 3 on page 56 as follows:

**Table 3**  
5'-thiophosphate RNA 2'-O-methyl hemimers targeted to siRNA mediated PTEN message

SEQ ID NO	Sequence 5'-3'
10	5' O <sub>2</sub> P(S)-O-UoUoUo GoUoCo UoCoUo GoGo Uo CoCoU*o U*oA*oC*o U*oU* 3'
11	5' O <sub>2</sub> P(S)-O-AoAoAo CoAoGo AoGoAo CoCo Ao GoGoAo A*oU*oG*o A*oA* 3'
12	5' O <sub>2</sub> P(S)-O-UsUsUs GsUsCs UsCsUs GsGsUs CsCsUs U*sA*sC*s U*sU* 3'

U\* = 2'-O-methyluridine, A\* = 2'-O-methyladenosine, C\* = 2'-O-methylcytidine, G\* = 2'-O-methylguanosine, o = PO, s = PS

DOCKET NO.: ISIS-5582  
Application No.: 10/510,667  
Preliminary Amendment - First Action Not Yet Received

PATENT

Please amend Table 8 on pages 60-61 as follows:

**Table 8**

5'-dDoxy-5'-Thiophosphoricacid RNA 2'-*O*-methyl hemimers targeted to siRNA mediated PTEN message

SEQ ID NO	Sequence 5'-3'
<b>25</b>	5' O <sub>2</sub> P(O)-S-UoUoUo GoUoCo UoCoUo GoGo Uo CoCoU*o U*oA*oC*o U*oU* 3'
<b>26</b>	5' O <sub>2</sub> P(O)-S-AoAoAo CoAoGo AoGoAo CoCo Ao GoGoAo A*oU*oG*o A*oA* 3'
<b>27</b>	5' O <sub>2</sub> P(O)-S-UsUsUs GsUsCs UsCsUs GsGsUs CsCsUs U*sA*sC*s U*sU* 3'

U\* = 2'-*O*-methyluridine, A\* = 2'-*O*-methyladenosine, C\* = 2'-*O*-methylcytidine, G\* = 2'-*O*-methylguanosine, o = PO, s = PS

Please amend Table 13 on page 65 as follows:

**Table 13**

5'-deoxy-5'-dithiophosphoricacid RNA 2'-*O*-methyl hemimers targeted to siRNA mediated PTEN message

SEQ ID NO	Sequence 5'-3'
<b>40</b>	5' O <sub>2</sub> P(S)-S-UoUoUo GoUoCo UoCoUo GoGo Uo CoCoU*o U*oA*oC*o U*oU* 3'
<b>41</b>	5' O <sub>2</sub> P(S)-S-AoAoAo CoAoGo AoGoAo CoCo Ao GoGoAo A*oU*oG*o A*oA* 3'
<b>42</b>	5' O <sub>2</sub> P(S)-S-UsUsUs GsUsCs UsCsUs GsGsUs CsCsUs U*sA*sC*s U*sU* 3'

U\* = 2'-*O*-methyluridine, A\* = 2'-*O*-methyladenosine, C\* = 2'-*O*-methylcytidine, G\* = 2'-*O*-methylguanosine, o = PO, s = PS

Please amend the last paragraph on page 73 as follows:

**DOCKET NO.: ISIS-5582**  
**Application No.: 10/510,667**  
**Preliminary Amendment - First Action Not Yet Received**

**PATENT**

For example, a duplex comprising an antisense strand having the sequence CGAGAGGCAGGACGGACCG (SEQ ID NO.: 64) and having a two-nucleobase overhang of deoxythymidine(dT) would have the following structure:

**SEQ ID NO.**

65            cgagaggcggacgggaccgTT        Antisense  
                ||||||||| Strand  
66            TTgctctccgcctgccctggc        Complement